The estimated Net Worth of Vickie S Reed is at least $1.29 Milione dollars as of 14 January 2022. Ms Reed owns over 533 units of Mirati Therapeutics Inc stock worth over $902,160 and over the last 5 years she sold MRTX stock worth over $388,429.
Ms has made over 4 trades of the Mirati Therapeutics Inc stock since 2021, according to the Form 4 filled with the SEC. Most recently she sold 533 units of MRTX stock worth $64,216 on 14 January 2022.
The largest trade she's ever made was selling 779 units of Mirati Therapeutics Inc stock on 6 January 2021 worth over $165,327. On average, Ms trades about 201 units every 31 days since 2020. As of 14 January 2022 she still owns at least 15,369 units of Mirati Therapeutics Inc stock.
You can see the complete history of Ms Reed stock trades at the bottom of the page.
Vickie S. Reed is the Sr. VP & Chief Accounting Officer at Mirati Therapeutics Inc.
Ms Reed is 59, she's been the Sr. VP & Chief Accounting Officer of Mirati Therapeutics Inc since . There are 8 older and 10 younger executives at Mirati Therapeutics Inc. The oldest executive at Mirati Therapeutics Inc is Bruce Carter, 76, who is the Independent Director.
Vickie's mailing address filed with the SEC is C/O EVOKE PHARMA, INC., 420 STEVENS AVENUE, SUITE 230, SOLANA BEACH, CA, 92075.
Over the last 11 years, insiders at Mirati Therapeutics Inc have traded over $179,669,845 worth of Mirati Therapeutics Inc stock and bought 8,779,906 units worth $186,410,608 . The most active insiders traders include Healthcare Master Fund Ltd ..., Capital Advisors Llc Aghaza... e Bros. Advisors Lp Baker Bro.... On average, Mirati Therapeutics Inc executives and independent directors trade stock every 22 days with the average trade being worth of $5,885,145. The most recent stock trade was executed by Benjamin Hickey on 16 January 2024, trading 1,597 units of MRTX stock currently worth $94,255.
mirati therapeutics develops molecularly targeted, single agent and immuno-oncology combination therapies intended to treat cancer. mirati's approach combines the three most important factors in oncology drug development, 1) researching and developing drug candidates that target genetic and epigenetic drivers of cancer, 2) designing creative and agile clinical development strategies that select for patients whose tumors are dependent on specific driver alterations, and 3) leveraging a highly accomplished oncology precision medicine leadership team. the mirati team uses a blueprint – proven by their prior work – for developing potential breakthrough cancer therapies, with accelerated development paths, in order to improve outcomes for patients. mirati is advancing three drug candidates through clinical development for multiple oncology indications.
Mirati Therapeutics Inc executives and other stock owners filed with the SEC include: